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IgA nephropathy (IgAN) is the most common glomerulonephritis worldwide, but its etiologic mechanisms are still poorly
understood. Different prevalences among ethnic groups and familial aggregation, together with an increased familial
risk, suggest important genetic inﬂuences on its pathogenesis. A locus for familial IgAN, called “IGAN1,” on chromosome
6q22-23 has been described, without the identiﬁcation of any responsible gene. The partners of the European IgAN
Consortium organized a second genomewide scan in 22 new informative Italian multiplex families. A total of 186 subjects
(59 affected and 127 unaffected) were genotyped and were included in a two-stage genomewide linkage analysis. The
regions 4q26-31 and 17q12-22 exhibited the strongest evidence of linkage by nonparametric analysis (best Pp .0025
and .0045, respectively). These localizations were also supported by multipoint parametric analysis, in which peak LOD
scores of 1.83 ( ) and 2.56 ( ) were obtained using the affected-only dominant model, and by allowanceap 0.50 ap 0.65
for the presence of genetic heterogeneity. Our results provide further evidence for genetic heterogeneity among families
with IgAN. Evidence of linkage to multiple chromosomal regions is consistent with both an oligo/polygenic and a
multiple-susceptibility-gene model for familial IgAN, with small or moderate effects in determining the pathological
phenotype. Although we identiﬁed new candidate regions, replication studies are required to conﬁrm the genetic con-
tribution to familial IgAN.
From the Medical Genetic Service, IRCCS–Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy (L.B.; M.D.P.; M.E.; L.Z.); Renal Unit,
University of Bari, Bari, Italy (G.C.; D.D.T.; F.P.S.); Department of Medical and Molecular Genetics, King’s College London School of Medicine at Guy’s,
King’s College and St. Thomas’ Hospitals, London (P.F.); Istituto di Genetica delle Popolazioni–CNR, Alghero, Italy (P.F.); Renal Unit, Spedali Civili,
Brescia, Italy (F.S.; M.F.); Genetic Unit, University of Torino, Torino, Italy (A.A.); Genetic Unit, University of Trieste, Trieste, Italy (S.B.); Division of
Nephrology and Immunology (J.F.; P.R.M.) and Institute of Human Genetics, RWTH University of Aachen, Aachen, Germany (K.Z.); and Renal Unit,
Aristotelian University of Thessaloniki, Thessaloniki, Greece (E.A.; D.K.)
Received March 22, 2006; accepted for publication October 9, 2006; electronically published November 3, 2006.
Address for correspondence and reprints: Dr. F. P. Schena, Renal Unit, Department of Emergency and Organ Transplant, University of Bari, Policlinico,
Piazza G. Cesare 11, 70124, Bari, Italy. E-mail: fp.schena@nephro.uniba.it
* These two authors contributed equally to this work.
Am. J. Hum. Genet. 2006;79:1130–1134.  2006 by The American Society of Human Genetics. All rights reserved. 0002-9297/2006/7906-0017$15.00
IgA nephropathy (IgAN [MIM 161950]) is the most com-
mon form of primary glomerulonephritis worldwide. The
diagnosis is based on the occurrence of mesangial IgA de-
posits in the glomeruli in the presence of recurrent epi-
sodes of intrainfectious macroscopic hematuria or persis-
tent microscopic hematuria and/or proteinuria. Abnormal
deglycosylated IgA1 synthesis, selective mesangial IgA1
deposition with ensuing mesangial cell proliferation, and
extracellular matrix expansion lead to renal ﬁbrosis, with
molecular mechanisms still poorly understood. Approxi-
mately 20%–50% of patients older than 30 years develop
end-stage renal disease within 20 years after the onset of
the disease.1
IgAN may occur in a sporadic or familial form. Familial
IgANwas ﬁrst described in two families withHLA-identical
brothers.2,3 After these reports were published, nuclear
families with IgAN were reported worldwide.4–7 The fa-
milial clustering and the striking ethnic variation in prev-
alence are suggestive of an important genetic component
in the pathogenesis of the disease. IgAN does not exhibit
basic Mendelian segregation patterns, although an in-
creased risk of the disease was observed in close relatives
of the probands.8
In an attempt to identify genes that underlie this dis-
ease, an initial genomewide scan was performed with 30
multiplex families with IgAN, of which 24 were from Italy.
This study identiﬁed the IGAN1 locus on 6q22-23, in link-
age with IgAN. It yielded a signiﬁcant LOD score of 5.6
in 60% of the linked families, with the assumption of an
autosomal dominant mode of inheritance with incom-
plete penetrance.9
Since that ﬁrst study, the partners of the European IgAN
Consortium have recruited new informative families to
better elucidate the genetic determination of the disease.10
The current study is a second-generation genomewide
scan to search for regions involved in IgAN susceptibility,
performed in a completely independent subset of 22 Ital-
ian multiplex families with IgAN. Recruitment strategies
and criteria for diagnosis have been reported elsewhere
and are freely available on the European IgANConsortium
Web site.10 Written informed consent was obtained from
all participating patients and relatives before they entered
the study. They were interviewed, and all personal and
relevant clinical and laboratory data were recorded and
stored in the IgAN Consortium database. At the time of
the interview, a blood sample was collected for DNA ex-
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Figure 1. Summary of the ﬁrst-stage linkage results of multipoint linkage analysis of the data set of 16 multiplex Italian families
with IgAN. ch p Chromosome.
traction, and a urinalysis was performed for all family
members. Recurrent episodes of macroscopic hematuria
were considered an indication for kidney biopsy. After uri-
nalysis, relatives withmicroscopic hematuria andnegative
results of urine culture underwent Addis count with con-
trast phase microscopy and renal ultrasonography and
were checked systematically once a year. Individuals with
secondary forms of IgAN (systemic lupus erythematosus
[MIM 152700], mixed cryoglobulinemia [MIM 123550],
and chronic hepatitis) were excluded. Familial IgAN was
diagnosed when at least two family members had biopsy-
proven IgAN. The study plan was approved by the local
ethics committees. This study included 59 affected (37
male and 22 female) and 127 unaffected (52 male and 75
female) subjects. The unaffected subjects were probands’
ﬁrst-, second-, and third-degree relatives aged 118 years.
The number of patients affected with IgAN ranged from
two to four subjects in each family. Macrohematuria, mi-
crohematuria, and renal insufﬁciency at onset were pre-
sent in 18, 19, and 6 patients with IgAN, respectively. No
documentation was available for the others. Mean (SD)
age at renal biopsy was 29.6 13 years, serum creatinine
level was 1.15  0.5 mg/dl, daily proteinuria was 1.1 
1.2 g, and creatinine clearance was 93.3  30 ml/min.
These clinical characteristics were available for 48 patients
with IgAN and were missing for 11. All renal biopsy spec-
imens were classiﬁed, according to Lee’s classiﬁcation, as
“mild” (grade 1–2, ), “moderate” (grade 3, ),np 14 np 11
or “severe” (grade 4–5, ) histologic lesions. Thesenp 7
ﬁndings were missing for 16 patients because diagnosis of
IgAN was made in other hospitals using a different his-
tological classiﬁcation, and the biopsy samples were no
longer available for review. Hypertension was present in
15 (31%) of the patients. The mean duration of follow-up
was 12 8.5 years, and 16 patients (33.3%) reached end-
stage kidney disease.
DNA was extracted from whole-blood samples with the
use of commercial kits (Genomix [Talent] and Blood and
Cells Culture Midi DNA kit [Qiagen]). A two-stage ge-
nomewide scan was performed. In the ﬁrst stage, 382
highly polymorphic markers along the 22 autosomal
chromosomes, at ∼10 cM density, were typed in a subset
of 16 informative families; interesting regions were sub-
sequently investigated in the whole sample of 22 families.
The pedigrees of the families analyzed can be visualized
in the Registry–Clinical Finding Search Page of the Eu-
ropean IgAN Consortium Web site. Microsatellite markers
included in the ABI PRISM Linkage Mapping Set v2.5-
MD10 were analyzed using the ABI Prism 3100 capillary
electrophoresis apparatus (Applied Biosystems). GeneScan
3.7 and Genotyper 3.7 NT software were used for geno-
typing. Additional microsatellite markers, available in the
Marshﬁeld genetic map and the University of California–
Santa Cruz (UCSC) draft of the human genome, were ge-
notyped to increase the resolution of the genetic map in
the ﬁne mapping of the identiﬁed candidate regions. The
inheritance of each marker in all pedigrees was tested by
PedCheck for inconsistencies due to null alleles, mistyp-
ing, nonpaternity, or other errors, and repeat genotyping
was performed as necessary.11 All marker alleles were con-
sidered to have equal frequency.
Maximum-likelihood–based (LOD score) methods of
linkage analysis were used, with the assumption of an
autosomal dominant mode of inheritance, with disease-
allele frequency of 0.001 and estimated penetrance of
75%. The phenocopy rate was set at 0.01. Multipoint NPL
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Table 1. First-Stage Genomewide Scan Results Obtained by Analyzing 16 Multiplex Families with
IgAN: Most-Relevant Regions Identiﬁed by Parametric Linkage and NPL Analyses
Marker
Distance
from
p-ter
(cM)
Chromosome
Location
Linkage Analysis Results Candidate Interval
HLODa (a)
Nonparametric
LOD (P) Chromosomal Marker (Distance)
D4S402 124 4q26 … 1.68 (.0445) 4q22.1-31.2 …
D4S1575 132 4q28 1.19 (.35) … … D4S2964–D4S424 (56 cM)
D7S661 155 7q34 … 1.73 (.0388) 7q33-36.3 …
D7S798 168 7q36.3 1.19 (.25) … … D7S640–D7S2465 (43 cM)
D10S1653 40 10p13 1.39 (.15) … 10p13-15.3 …
D10S189 19 10p14 … 2.34 (.0093) … D10S249–D10S1653 (38 cM)
D17S798 53 17q11.2 1.00 (.40) … 17q11.2-23.3 …
D17S1868 64 17q21.32 … 2.63 (.0040) … D17S1857–D17S944 (39 cM)
D2S325 204 2q33.3 1.13 (.20) … 2q24.3-35 D2S2330–D2S2382 (44 cM)
D8S1784 106 8q22.3 … 1.8 (.0319) 8q21.3-24.21 D8S6270–D8S284 (37 cM)
D10S1693 137 10q26.11 1.08 (.44) … 10q23.33-26.2 D10S185–D10S217 (41 cM)
D12S79 125 12q24.21 … 1.97 (.0286) 12q23.3-24.33 D12S78–D12S1723 (53 cM)
D15S117 51 15q21.3 … 1.71 (.0412) 15q13.2-22.3 D15S165–D15S153 (42 cM)
a Data were obtained by assuming an autosomal dominant model of inheritance with incomplete penetrance (75%).
(NPLall statistic), parametric LOD score, and heterogeneity
LOD score (HLOD) were calculated using Genehunter12 in
the ﬁrst stage of the analysis and Simwalk213 in the sec-
ond, since some of the families included in the second
stage were too large to be analyzed with the exact method
implemented in Genehunter. The proportion of families
linked (a) was allowed to vary until the HLOD was max-
imized. Recent studies demonstrate that, although the es-
timated value of a is problematic when this method is
used, the HLOD score remains a powerful method for de-
tection of linkage in the presence of heterogeneity.14,15
Parametric LOD scores were also evaluated using an af-
fected-only strategy—that is, by assuming all unaffected
individuals as phenotypically unknown, since they may
not provide reliable information on the underlying dis-
ease-locus genotype for a complex disease.
First of all, we tested whether the families with IgANwere
linked to the previous locus IGAN1 on 6q22-23. We ana-
lyzed the markers D6S287, D6S1702, D6S1690, D6S1705,
D6S1040, and D6S262, which span a 9.5-cM region over-
lapping the locus IGAN1. Multipoint parametric analysis
yielded in the region maximum HLOD scores of 0.42 (ap
) and 1.05 ( ) for the affected-only approach,0.20 ap 0.45
whereas multipoint nonparametric analysis yielded .Pp .01
The overall results obtained from the ﬁrst-stage ge-
nomewide scan are represented in ﬁgure 1 and table 1.
Four loci yielding multipoint HLOD 1 and NPL P
were identiﬁed. The region 4q22.1-31.2 yielded max-.05
imum HLOD 1.19 ( ) and nonparametric LODap 0.35
1.68 ( ). The multipoint curves identiﬁed a 56-Pp .0445
cM interval bounded by markers D4S2964 and D4S424.
The region 7q33-36.3, spanning 43 cM between D7S640
and D7S2465, yielded maximum HLOD 1.19 ( )ap 0.25
and nonparametric LOD 1.73 ( ). The 38-cM re-Pp .0388
gion 10p13-15.3, bounded by D10S249 and D10S1653,
yielded maximum HLOD 1.39 ( ) and nonpara-ap 0.15
metric LOD 2.34 ( ). The region 17q11.2-23.3Pp .0093
yielded maximum HLOD 1.00 ( ) and nonpara-ap 0.40
metric LOD 2.63 ( ). The multipoint curves iden-Pp .0040
tiﬁed a 39-cM interval bounded by D17S1857 and
D17S944. Other loci showing only multipoint HLOD 1
or NPL were not further investigated. In partic-P .05
ular, the 44-cM region 2q24.3-35, between D2S2330 and
D2S2382, yielded HLOD 1.13 ( ); the 37-cM regionap 0.20
8q21.3-24.21, between D8S270 and D8S284, yielded NPL
1.8 ( ); the 41-cM region 10q23.33-26.2, betweenPp .0319
D10S185 and D10S217, yielded HLOD 1.08 ( );ap 0.44
the 53-cM region 12q23.3-24.33, between D12S78 and
D12S1723, yielded nonparametric LOD 1.97 ( );Pp .0286
and the 42-cM region 15q13.2-22.3, between D15S165
and D15S153, yielded nonparametric LOD 1.71 (Pp
). The analysis of the four regions identiﬁed in stage.0412
I was then extended to six other new collected families
with IgAN. In the ﬁnal sample of 22 families, only chro-
mosomes 4 and 17 provided HLOD scores 11 and P
values !.05 for the multipoint NPLall statistic of Simwalk2
(table 2). In particular, the NPL P value of .0059 and the
HLOD of 3.80 were obtained at D17S1868 when an af-
fected-only approach was used. The highest evidence in
the chromosome 4 region was reached at D4S402, with
an NPL P value of .0454 and an HLOD of 1.05 (ap
). These chromosomal regions were considered a high0.45
priority for ﬁne-mapping analysis.
Fifteen additional markers were genotyped between
D4S1572 and D4S424 (∼36 cM), with a ﬁnal average spac-
ing of ∼2 cM betweenmarkers; ﬁve additionalmarkerswere
genotyped between D17S798 and D17S944 (∼30 cM), with
a ﬁnal average spacing of ∼3.7 cM. The strongest evidence,
shown in table 3, was observed on 17q12-22, where HLOD
2.56 ( ) was obtained at D17S944 with use of theap 0.65
affected-onlymodel, and the peak NPL P value of .0045was
observed at D17S943, located ∼12 cM from D17S944. NPL
P values !.05 were observed in the whole 30-cM region. The
analysis of the region 4q26-31 yielded themaximumHLOD
www.ajhg.org The American Journal of Human Genetics Volume 79 December 2006 1133
Table 2. Results from Parametric Linkage and NPL Analyses Performed in 22
Families with IgAN in the Regions Identiﬁed in Stage I
Chromosome Marker Interval
Region Span
(cM)
Peak
Marker HLODa (a)
NPL
P
4 D4S2964–D4S424 91.3–147.4 D4S402 1.05 (.45) .0454
7 D7S640–D7S2465 146.9–191.1 D7S798 1.02 (.40) NSb
10 D10S249–D10S1653 .0–40.1 … !1 NSb
17 D17S798–D17S944 45.0–90.0 D17S1868 3.80 (1.0) .0059
a HLOD scores were calculated by assuming the dominant model, described in the text, and by using
an affected-only approach.
b NS p not signiﬁcant.
Table 3. Results from the Fine-Mapping Analysis of the
Regions 4q26-31 and 17q12-22, with Parametric Linkage
and NPL Analyses
Peak Marker Region
Region Span
(cM) HLODa (a) NPL P
D4S2965 4q26-31 117.0–147.0 1.83 (.50) .0025
D17S943 17q12-22 57.0–90.0 … .0045
D17S944 17q12-22 57.0–90.0 2.56 (.65) …
a HLOD scores were calculated by assuming the dominant model, de-
scribed in the text, and by using an affected-only approach.
1.83 ( ) and NPL at D4S2965; NPL P val-ap 0.50 Pp .0025
ues !.05 were obtained in an ∼32-cM region spanning
from D4S1513 to D4S424 (table 3). The pedigrees of the
larger families with genotypes and reconstructed haplo-
types are represented in ﬁgure 2.
Our data show that, besides IGAN1, the existence of at
least two other loci candidates contain causative and/or
susceptibility genes for familial IgAN. Although the fam-
ilies in our data set were similar from a clinical and de-
mographic point of view, these results and those obtained
for locus IGAN1 strongly pointed to genetic heterogeneity
in familial IgAN. The evidence of IgAN linked to multiple
chromosomal regions is consistent with both an oligo/
polygenic and a multiple-susceptibility-gene model for fa-
milial IgAN, all having a small or moderate effect in de-
termining the pathological phenotype, as observed in
complex diseases.
Despite the success of linkage studies in deﬁning regions
of the genome containing important disease loci, the pro-
cess is slow, and it is difﬁcult to convert this information
into genes and responsible DNA variants. The gene(s) as-
sociated with onset and/or progression of IgAN lying in
the IGAN1 locus has not yet been identiﬁed. A genome-
wide scan in a novel murine model identiﬁed a suscep-
tibility locus on chromosome 10 in a region syntenic to
human IGAN1.16 However, this animal model does not
fully resemble human IgAN, since hematuria is completely
absent, and there are fundamental differences between the
human and murine IgA system. The association of IGAN1
with mesangioproliferative glomerular injury with IgA de-
position emerges from this study. Our overall linkage anal-
ysis also suggests to search for the critical genes among
the 199 and 347 genes mapped in the regions 4q26-31
and 17q12-22, respectively. We carefully analyzed these
genes and identiﬁed the following potential candidate
genes of major interest located in 4q26-31: transient recep-
tor potential channel 3 (TRPC3 [MIM 602345]), interleukin-
2 (IL-2 [MIM 147680]), and interleukin-21 (IL-21 [MIM
605384]), which could be largely involved in the unbal-
anced T-helper 1/T-helper 2 immune response observed
in patients with IgAN.17–19 These genes should be inves-
tigated, to assess their role in the pathogenesis of IgAN.
Moreover, a recently published paper has evidenced an
altered gene-expression pattern in leukocytes of patients
with IgAN, through an Afﬁmetrix GeneChip microarray
experiment.20 Among the genes with increased expression,
we identiﬁed some candidate genes mapped in 17q12-22
and 6q22-23. The histone deacetylase 5 (HD5 [MIM 605315])
and granulin (GRN [MIM 138945]) genes on 17q12-22 could
be involved in immune-response deregulation. The serine/
threonine protein kinase (SGK [MIM 602958]) gene, localized
on chromosome 6q23, could induce extracellular matrix
expansion, which leads to renal ﬁbrosis. The vanin 3 (VNN3
[MIM606592]) gene, localized on6q23, couldbe implicated
in abnormal deglycosylated IgA1 synthesis, which repre-
sents another important pathogenic factor for IgAN.21
Our data suggest that newly found loci trigger or par-
ticipate in familial IgAN and that gene-gene and gene-
environment interactions may play an important role in
the development of this disease. Although we identiﬁed
new candidate regions, replication studies are required to
conﬁrm the genetic contribution in familial IgAN.
It is common to describe IgAN as a single disease, but
the present limited understanding of the etiology and
pathogenesis of IgAN does not yet provide evidence for
such a view. Mesangial IgA deposition and subsequent in-
jury may eventually turn out to represent a ﬁnal common
pathway of the glomerular response to a wide range of
causative and pathogenic processes. The major task in dis-
secting this complex disorder is not only to shed light on
its pathogenesis but also to provide potential targets for
treatment, screening, and prevention and to increase the
understanding of why some patients do not respond to
currently available treatments whereas others do.
Acknowledgments
We are grateful to the patients and relatives for their cooperation
in this study. We thank Mariella Mastrolonardo for her editorial
assistance. This project was supported by grants from the 5th
1134 The American Journal of Human Genetics Volume 79 December 2006 www.ajhg.org
Figure 2. Pedigrees of the families 1-4, 1-15, 2-18, 1-344, and
1-385, with genotypes and reconstructed haplotypes.
European Framework Programme (QLG1-CT-2000-00464), the
Ministero dell’Istruzione, Universita` e Ricerca (PRIN 2001-067748
and FIRB 2001-RBNE013JYM), theMinistero della Salute (RC2006),
and Centro di Eccellenza Genomica in Campo Biomedico ed Agra-
rio. The European IgAN Consortium partners thank the Italian re-
nal units that contributed to the diagnosis of IgAN in families and
the collection of DNA samples: Pediatric Nephrology, Perugia Hos-
pital (S.Maffei); Nephrology andDialysisUnit, BambinoGesu`Chil-
dren’s Research Hospital, Roma (F. Emma); Renal Unit, University
of Foggia (L. Gesualdo); Renal Unit, Martina Franca (A. L.Marangi);
Renal Unit, Santa Maria degli Angeli Hospital, Putignano (M.Gian-
nattasio); Renal Unit, Ospedale Riuniti, Ancona, (G.M. Frasca`); and
Laboratory on Pathophysiology of Uremia, G. Gaslini Children’s
Hospital, Genova (G. M. Ghiggeri).
Web Resources
Accession numbers and URLs for data presented herein are as
follows:
European IgAN Consortium Web site, http://www.igan.net/
Marshﬁeld genetic map, http://www.marshﬁeldclinic.org/research/
genetics/default.html
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for IgAN, systemic lupus erythematosus,
mixed cryoglobulinemia, TRPC3, IL-2, IL-21, HD5, GRN, SGK,
and VNN3)
UCSC Genome Browser, http://www.genome.ucsc.edu/
References
1. Schena FP, Coppo R (2005) IgA nephropathies. In: Davison
AM, Cameron JS, Gru¨nfeld JP, Ponticelli C, Ritz E, Winearls
CG, van T Persele C (eds) Oxford textbook of clinical neph-
rology, 3rd ed. Oxford University Press, Oxford, pp 469–501
2. Tolkoff-Rubin NE, Cosimi AB, Fuller T, Rublin RH, Colvin RB
(1978) IgA nephropathy in HLA-identical siblings. Trans-
plantation 26:430–433
3. Sabatier JC, Ducret F, Colon S, Genin C, Berthoux FC (1978)
Intercapillary glomerulonephritis with IgA deposits in 2 HLA
identical brothers. J Urol Nephrol Paris 84:672–675
4. Levy M (1993) Multiplex families in IgA nephropathy. Con-
trib Nephrol 104:46–53
5. Li PK, Burns AP, So AK, Lai KN, Rees AJ (1992) Familial IgA
nephropathy: a study of HLA class II allogenotypes in a Chi-
nese kindred. Am J Kidney Dis 20:458–462
6. Scolari F, Amoroso A, Savoldi S (1999) Familial clustering of
IgA nephropathy: further evidence in an Italian population.
Am J Kidney Dis 33:857–865
7. Kabasakal C, Keskinoglu A, Mir S, Basdemir G (1997) IgA
nephropathy occurring in two siblings of three families. Turk
J Pediatr 39:395–401
8. Schena FP, Cerullo G, Rossini M, Lanzilotta SG, D’Altri C,
Manno C (2002) Increased risk of end-stage renal disease in
familial IgA nephropathy. J Am Soc Nephrol 13:453–460
9. Gharavi AG, Yan Y, Scolari F, Schena FP, Frasca GM, Ghiggeri
GM, Cooper K, Amoroso A, Viola BF, Battini G, Caridi G,
Canova C, Farhi A, Subramanian V, Nelson-Williams C,
Woodford S, Julian BA, Wyatt RJ, Lifton RP (2000) IgA ne-
phropathy, the most common cause of glomerulonephritis,
is linked to 6q22-23. Nat Genet 26:354–357
10. Schena FP, Cerullo G, Torres DD, Scolari F, Foramitti M, Amo-
roso A, Pirrulli D, Floege J, Mertens PR, Zerres K, Alexopoulos
E, Kirmizis D, Zelante L, Bisceglia L, Ghiggeri GM, Frasca GM,
European IgA Nephropathy Consortium (2005) The IgA Ne-
phropathy Biobank: an important starting point for the ge-
netic dissection of a complex trait. BMC Nephrol 6:14
11. O’Connell JR, Weeks DE (1998) PedCheck: a program for
identiﬁcation of genotype incompatibilities in linkage anal-
ysis. Am J Hum Genet 63:259–266
12. Kruglyak L, Daly MJ, Reeve-Daly MP, Lander ES (1996) Para-
metric and nonparametric linkage analysis: a uniﬁed multi-
point approach. Am J Hum Genet 58:1347–1363
13. Sobel E, Lange K (1996) Descent graphs in pedigree analysis:
applications to haplotyping, location scores, and marker
sharing statistics. Am J Hum Genet 58:1323–1337
14. Greenberg DA, Abreu PC (2001) Determining trait locus po-
sition from multipoint analysis: accuracy and power of three
different statistics. Genet Epidemiol 21:299–314
15. Hodge SE, Vieland VJ, Greenberg DA (2002) HLODs remain
powerful tools for detection of linkage in the presence of
genetic heterogeneity. Am J Hum Genet 70:556–559
16. Suzuki H, Suzuki Y, Yamanaka T, Hirose S, Nishimura H, Toei
J, Horikoshi S, Tomino Y (2005) Genome-wide scan in a novel
IgA nephropathy model identiﬁes a susceptibility locus on
murine chromosome 10, in a region syntenic to human IGAN1
on chromosome 6q22-23. J Am Soc Nephrol 16:1289–1299
17. Lim CS, Zheng S, Kim YS, Ahn C, Han JS, Kim S, Lee JS, Chae
DW, Koo JR, Chun RW, Noh JW (2001) Th1/Th2 predomi-
nance and proinﬂammatory cytokines determine the clini-
copathological severity of IgA nephropathy. Nephrol Dial
Transplant 16:269–275
18. Ebihara I, Hirayama K, Yamamoto S, Muro K, Yamagata K,
Koyama A (2001) Th2 predominance at the single-cell level
in patients with IgA nephropathy. Nephrol Dial Transplant
16:1783–1789
19. Schena FP, Cerullo G, Torres DD, Scolari F, Foramitti M, Amo-
roso A, Pirulli D, Floege J, Mertens PR, Zerres K, Alexopoulos
E, Kirmizis D, Zelante L, Bisceglia L (2006) Role of interferon-
gamma gene polymorphisms in susceptibility to IgA nephro-
pathy: a family-based association study. Eur J Hum Genet 14:
488–496
20. Preston GA,Waga I, Alcorta DA, Sasai H,MungerWE, Sullivan
P, Phillips B, Jennette JC, Falk RJ (2004) Gene expression pro-
ﬁles of circulating leukocytes correlate with renal disease ac-
tivity in IgA nephropathy. Kidney Int 65:420–430
21. Novak J, Tomana M, Matousovic K, Brown R, Hall S, Novak
L, Julian BA, Wyatt RJ, Mestecky J (2005) IgA1-containing
immune complexes in IgA nephropathy differentially affect
proliferation of mesangial cells. Kidney Int 67:504–513
